NBTX earnings: next report 2026-09-30, real EPS beat/miss history, analyst consensus Buy, P/E -68.55. Updated 2026-07-23.
Nanobiotix (NBTX) Research Hub
Nanobiotix (NBTX) trades on NASDAQ, FR in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 37.01 USD (+1.01%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -68.55, market cap 2.01B. This hub links to the full technical, earnings and options research available for NBTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, FR |
| Last close | 37.01 USD (+1.01%) |
| 52-week range | 33.37 USD – 45.74 USD |
| Trend regime | Range |
| 14-day RSI | 47.6 (Neutral) |
| Trailing P/E | -68.55 |
| Market cap | 2.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-30 |
Available research for NBTX
Covered Call on NBTX: how it works, illustrative setup around the real 37.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NBTX: how it works, illustrative setup around the real 37.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NBTX: how it works, illustrative setup around the real 37.01 USD price, max profit/loss, breakeven and when to use it. Educational.
NBTX technical analysis: range, last 37.01 USD, RSI 47.6, 52w range 33.37 USD–45.74 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NBTX in?
Nanobiotix (NBTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, FR.
Is NBTX in an uptrend or downtrend?
As of 2026-09-11, NBTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NBTX's trailing P/E ratio?
NBTX's trailing P/E is -68.55, with a market cap of 2.01B. See the earnings research page for full valuation detail.
When does NBTX next report earnings?
NBTX is next scheduled to report earnings on 2026-09-30, with a consensus EPS estimate of -0.31556 USD.